Eli Lilly and Company (NYSE:LLY) Issues FY 2026 Earnings Guidance

Eli Lilly and Company (NYSE:LLY) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 35.500-36.500 for the period, compared to the consensus EPS estimate of 36.120. The company issued revenue guidance of $85.0 billion-$87.0 billion, compared to the consensus revenue estimate of $85.4 billion.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Berenberg Bank increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Barclays boosted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. UBS Group boosted their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Trading Up 4.2%

NYSE LLY traded up $46.75 on Wednesday, reaching $1,162.43. The company had a trading volume of 4,559,307 shares, compared to its average volume of 3,130,122. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The stock’s 50 day moving average is $1,154.75 and its 200-day moving average is $1,044.52. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.09 trillion, a price-to-earnings ratio of 41.32, a PEG ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.06 by $2.32. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.69 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the previous year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts predict that Eli Lilly and Company will post 34.91 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Blowout second-quarter results: Lilly reported non-GAAP earnings of $8.38 per share, well above the roughly $6.06 analyst consensus, while revenue rose 47.7% year over year to $22.97 billion versus expectations of about $20.69 billion. Lilly second-quarter earnings report
• Positive Sentiment: GLP-1 demand is driving growth: Strong volume for diabetes drug Mounjaro and obesity treatment Zepbound fueled the revenue and profit beat, with newer pipeline products adding to Lilly’s long-term growth outlook. Lilly earnings and outlook article
• Positive Sentiment: Full-year outlook raised: Lilly now expects 2026 revenue of $85 billion to $87 billion, up from its previous $82 billion to $85 billion forecast. It also issued EPS guidance of $35.50 to $36.50, supporting estimates of continued earnings momentum. Reuters Lilly revenue forecast article
• Positive Sentiment: Additional commercial and pipeline catalysts: CVS Health is expanding its weight-management program through a Lilly partnership, while Lilly is providing limited early access to experimental obesity drug retatrutide and advancing cancer drug olomorasib. These developments strengthen Lilly’s distribution and future-product narratives. Lilly financial results and pipeline update
• Negative Sentiment: Capacity and valuation remain risks: Executives acknowledged that manufacturing and supply capacity could limit how quickly Lilly converts virtually unlimited GLP-1 demand into sales. At roughly a $1.1 trillion market capitalization and a forward-looking valuation near 41 times earnings, the stock also has limited room for execution disappointments.

Institutional Trading of Eli Lilly and Company

Large investors have recently made changes to their positions in the company. Mcguire Capital Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth about $38,000. Gilpin Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $54,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Eli Lilly and Company by 57.1% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 55 shares of the company’s stock worth $59,000 after purchasing an additional 20 shares during the period. Turning Point Benefit Group Inc. acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $56,000. Finally, Swiss RE Ltd. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $173,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.